https://oncimmune.sperlingsandbox.com/resources/ 2025-08-04T10:09:04+00:00 https://oncimmune.sperlingsandbox.com/autoantibodies-as-biomarkers-in-immuno-oncology/ 2022-08-15T20:21:11+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/08/autoantibodies-thumbnail.webp https://oncimmune.sperlingsandbox.com/novel-biomarkers-of-immunotherapy-outcomes-and-immune-related-adverse-events/ 2022-08-15T20:21:28+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/08/2-1.webp https://oncimmune.sperlingsandbox.com/oncimmune-receives-queens-award-for-enterprise-in-innovation-2022/ 2022-08-15T20:24:18+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/04/news-queen-awards.webp https://oncimmune.sperlingsandbox.com/oncimmune-signs-contracts-with-us-based-clinical-stage-biopharmaceutical-companies-developing-immunotherapies-one-of-which-is-focused-on-car-nk-cell-therapies/ 2022-08-15T20:27:23+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/04/us-based-contract.webp https://oncimmune.sperlingsandbox.com/follow-on-contract-signed-with-leading-us-medical-research-organisation-to-validate-previous-profiling-in-covid-19/ 2022-08-15T20:28:50+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/03/medical-research-COVID-19.webp https://oncimmune.sperlingsandbox.com/immunoinsights-signs-contract-with-leading-top-10-global-pharmaceutical-company-to-profile-biomarkers-in-chronic-inflammatory-demyelinating-polyradiculoneuropathy-cidp/ 2022-08-15T20:29:38+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/03/top-10-global-pharma.webp https://oncimmune.sperlingsandbox.com/immunoinsights-and-synexa-life-sciences-sign-go-to-market-service-partnership/ 2022-08-15T20:31:47+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/07/5-1.webp https://oncimmune.sperlingsandbox.com/contract-signed-with-verily-life-sciences-an-alphabet-company-to-profile-autoantibodies-for-long-covid-19/ 2022-08-15T20:32:05+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/07/6-1.webp https://oncimmune.sperlingsandbox.com/poster-cancer-immunotherapy-array-a-novel-screening-tool-for-immune-system-profiling-in-cancer-immunotherapy-bridging-autoimmunity-and-cancer/ 2022-08-16T13:47:12+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/07/poster-2-for-click-for-more-1.png https://oncimmune.sperlingsandbox.com/1772-2/ 2022-08-16T13:50:51+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/07/Poster-1-for-click-for-more-1.png https://oncimmune.sperlingsandbox.com/autoantibody-profiling-in-prostvac-and-ipilimumab-treated-prostate-cancer-patients-reveals-potential-biomarkers-of-immune-related-adverse-events/ 2022-08-16T16:18:26+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/08/publication-screeenshot.png https://oncimmune.sperlingsandbox.com/paradoxical-sex-specific-patterns-of-autoantibodies-response-to-sars-cov-2-infection/ 2022-08-19T20:07:39+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/08/JTM_Paradoxical-screenshot.webp https://oncimmune.sperlingsandbox.com/immunoinsights-platform/ 2022-10-17T13:48:16+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/08/Brochure.webp https://oncimmune.sperlingsandbox.com/app/uploads/2022/08/Brochure.webp https://oncimmune.sperlingsandbox.com/poster-autoantibody-profiling-in-prostvac-and-ipilimumab-treated-prostate-cancer-patients-reveals-potential-biomarkers-of-immune-related-adverse-events/ 2022-10-17T13:52:33+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/07/poster3-for-click-for-more-1.png https://oncimmune.sperlingsandbox.com/poster-multiplexed-autoantibody-profiling-of-patients-with-metastatic-urothelial-carcinoma-receiving-immune-checkpoint-inhibitors-or-platinum-based-chemotherapy-oncimmune-collaboration-asco-genito/ 2022-10-17T13:53:41+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2022/07/Posters-2022-click-for-more-1.webp https://oncimmune.sperlingsandbox.com/siemens-healthineers-and-oncimmune-partner-to-improve-malignancy-risk-assessment-of-indeterminate-pulmonary-nodules-ipns/ 2023-02-20T14:25:49+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2023/02/Siemens-Lung-Web-NEws-1200-%C3%97657-px.png https://oncimmune.sperlingsandbox.com/oncimmune-to-participate-at-the-asco-2023-meeting/ 2023-04-28T15:50:51+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2023/04/ASCOAM23LinkedIn.jpg https://oncimmune.sperlingsandbox.com/oncimmune-announces-strategy-updates-and-changes-to-the-board-of-directors/ 2023-10-12T12:42:51+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2023/10/Knowledge-Centre-News-1200-%C3%97-800-px-1.png https://oncimmune.sperlingsandbox.com/martine-gouldstone-ceo-updates-investors-on-oncimmunes-new-strategy/ 2023-11-22T22:21:58+00:00 https://oncimmune.sperlingsandbox.com/oncimmunes-ceo-martin-gouldstone-speaks-to-vox-market-about-the-companys-new-strategy-progress/ 2023-11-26T23:23:27+00:00 https://oncimmune.sperlingsandbox.com/progress-against-strategy/ 2023-11-30T09:41:25+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2023/11/News.png https://oncimmune.sperlingsandbox.com/ceo-martin-gouldstone-speaks-to-proactive-london-about-the-positive-results-of-the-new-strategy/ 2023-12-02T20:45:15+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2023/12/News-1.png https://oncimmune.sperlingsandbox.com/martin-gouldstone-ceo-of-oncimmune-speaks-on-ip_talks/ 2023-12-12T14:50:12+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2023/12/News-11.png https://oncimmune.sperlingsandbox.com/oncimmune-provides-update-on-recent-trading-and-the-outlook-for-2024/ 2024-02-29T11:01:49+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/02/AR-News2.png https://oncimmune.sperlingsandbox.com/app/uploads/2024/02/AR-News2.png https://oncimmune.sperlingsandbox.com/ceo-martin-gouldstone-speaks-to-vox-markets-about-oncimmune-and-provides-a-commercial-strategy-update/ 2024-03-12T15:12:00+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/03/VoxMarketInterview.png https://oncimmune.sperlingsandbox.com/ceo-martin-gouldstone-speaks-to-proactive-london-about-the-companys-pivot-aims-for-robust-growth-in-2024/ 2024-03-12T15:27:46+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/03/Proactive-Interview.png https://oncimmune.sperlingsandbox.com/oncimmune-targets-age-related-diseases-with-biomarker-research/ 2024-04-23T09:33:38+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/04/Ageing.png https://oncimmune.sperlingsandbox.com/video-oncimmune-scientists-decode-autoantibody-reactome-using-xmap-technology/ 2024-05-14T14:51:06+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/05/video-lumn.png https://oncimmune.sperlingsandbox.com/oncimmune-announces-six-month-interim-results/ 2024-05-21T09:31:23+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/05/Interim2.png https://oncimmune.sperlingsandbox.com/2833-2/ 2024-05-22T16:06:07+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/05/News2.png https://oncimmune.sperlingsandbox.com/ceomartin-gouldstone-speaks-to-vox-markets-about-the-companys-six-month-interim-results/ 2024-05-23T12:56:59+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/05/NewsVOX.png https://oncimmune.sperlingsandbox.com/comprehensive-multiplexed-autoantibody-profiling-of-patients-with-advanced-urothelial-cancer/ 2024-06-27T14:24:33+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/06/Blog2.png https://oncimmune.sperlingsandbox.com/us-1-5m-contract-win-with-top-10-pharma-company/ 2024-08-09T06:01:45+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/08/IgE-Press-Release.png https://oncimmune.sperlingsandbox.com/ceo-martin-gouldstone-speaks-to-vox-markets-about-the-significance-of-recent-1-5m-contract-win/ 2024-08-15T11:49:20+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/08/NewsVOX1.5.png https://oncimmune.sperlingsandbox.com/additional-contract-win-with-top-10-pharma-company/ 2024-09-03T10:22:55+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/09/PRESS-22.png https://oncimmune.sperlingsandbox.com/ceo-martin-gouldstone-speaks-to-proactive-london-about-the-the-companys-six-month-interim-results/ 2024-09-03T10:27:52+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/05/ProactiveInterviewMay24.png https://oncimmune.sperlingsandbox.com/ceo-martin-gouldstone-speaks-to-proactive-london-about-the-companys-second-contract-win-with-top-10-pharma-company/ 2024-09-03T12:40:52+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/09/PROACTPRESS.png https://oncimmune.sperlingsandbox.com/advancing-precision-medicine-insights-from-bio2024/ 2024-09-04T12:08:04+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/09/blog.png https://oncimmune.sperlingsandbox.com/2898-2/ 2024-09-10T10:49:19+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/09/VOX-Q7A.png https://oncimmune.sperlingsandbox.com/ceo-martin-gouldstone-speaks-to-proactive-about-the-companys-progress-and-continuous-traction/ 2024-09-10T11:14:43+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/09/NEW-PROACTNEWS3.png https://oncimmune.sperlingsandbox.com/trading-update/ 2024-10-31T10:27:39+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/10/Trading-Update.png https://oncimmune.sperlingsandbox.com/ceo-martin-gouldstone-speaks-to-proactive-about-securing-three-new-contracts-the-strengthening-of-the-companys-revenue-pipeline-and-commercial-momentum/ 2024-11-06T11:34:16+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/11/Trading-UP_Proact.png https://oncimmune.sperlingsandbox.com/ceo-martin-gouldstone-qa-with-vox-markets/ 2024-11-13T15:41:26+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2024/11/Vox-Markets-QA.png https://oncimmune.sperlingsandbox.com/redefining-microbiome-pathology-through-autoantibody-biomarkers/ 2025-02-04T14:03:32+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2025/02/MICRO.jpg https://oncimmune.sperlingsandbox.com/ceo-martin-gouldstone-qa-with-vox-markets-2/ 2025-02-04T16:04:53+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2025/02/VOX-MARKETS.png https://oncimmune.sperlingsandbox.com/celebrating-the-women-of-oncimmune-on-international-womens-day/ 2025-03-08T08:00:52+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2025/03/IWD.png https://oncimmune.sperlingsandbox.com/app/uploads/2024/12/Petra-Budde-e1752679698749.jpg https://oncimmune.sperlingsandbox.com/app/uploads/2025/03/7.png https://oncimmune.sperlingsandbox.com/app/uploads/2025/03/6.png https://oncimmune.sperlingsandbox.com/app/uploads/2025/03/Untitled.jpg https://oncimmune.sperlingsandbox.com/autoantibodies-in-neurology-pioneering-new-paths-in-disease-detection-and-treatment/ 2025-03-12T10:57:41+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2025/02/neuro-blog-updated-image-1.png https://oncimmune.sperlingsandbox.com/alden-scientific-acquires-oncimmune-germany-gmbh-expanding-global-leadership-in-multi-omic-research-and-precision-medicine/ 2025-07-22T16:50:22+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2025/07/Alden-Scientific-Press-Release.png https://oncimmune.sperlingsandbox.com/proust-on-discovery-why-alden-scientific-acquired-oncimmune-gmbh/ 2025-08-04T10:09:04+00:00 https://oncimmune.sperlingsandbox.com/app/uploads/2025/07/14-scaled.png